During the past decade, Maine Center for Cancer Medicine and Blood Disorders - Scarborough conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 14 clinical trials were completed, i.e. on average, 1400% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Maine Center for Cancer Medicine and Blood Disorders - Scarborough" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 12 trials, followed by "Radiation Therapy Oncology Group" with 6 trials sponsored, "Celgene" with 4 trials sponsored, "NCIC Clinical Trials Group" with 3 trials sponsored and "Amgen" with 3 trials sponsored. Other sponsors include 20 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maine Center for Cancer Medicine and Blood Disorders - Scarborough" #1 collaborator was "National Cancer Institute (NCI)" with 24 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "NCIC Clinical Trials Group" with 3 trials as a collaborator, "SWOG Cancer Research Network" with 3 trials as a collaborator and "Bayer" with 2 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Maine Center for Cancer Medicine and Blood Disorders - Scarborough" are "Breast Cancer" (12 trials), "Prostate Cancer" (6 trials), "Lung Cancer" (5 trials), "Head and Neck Cancer" (3 trials) and "Multiple Myeloma" (3 trials). Many other conditions were trialed in "Maine Center for Cancer Medicine and Blood Disorders - Scarborough" in a lesser frequency.

Most popular intervention types in "Maine Center for Cancer Medicine and Blood Disorders - Scarborough" are "Drug" (39 trials), "Biological" (8 trials), "Procedure" (8 trials), "Radiation" (8 trials) and "Other" (6 trials). Other intervention types were less common.

The name of intervention was led by "docetaxel" (7 trials), "cisplatin" (5 trials), "paclitaxel" (5 trials), "doxorubicin hydrochloride" (4 trials) and "filgrastim" (4 trials). Other intervention names were less common.

The vast majority of trials in "Maine Center for Cancer Medicine and Blood Disorders - Scarborough" are 32 trials for "All" genders, 14 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "Maine Center for Cancer Medicine and Blood Disorders - Scarborough". undefined are not yet recruiting, undefined are recruiting, 9 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Maine Center for Cancer Medicine and Blood Disorders - Scarborough, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Maine Center for Cancer Medicine and Blood Disorders - Scarborough, 2 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".